Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk

Fig. 1

PFS based on cytogenetic risk status. PFS in the ITT/biomarker risk population (patients in the ITT population who met the biomarker criteria for risk assessment): a standard cytogenetic risk patients and b high cytogenetic risk patients. PFS in patients with 1 prior line of therapy: c standard cytogenetic risk patients and d high cytogenetic risk patients. CI, confidence interval; D-Vd, daratumumab plus bortezomib/dexamethasone; HR, hazard ratio; ITT intent-to-treat; PFS, progression-free survival; Vd, bortezomib/dexamethasone

Back to article page